A new study has revealed that a combination of chemotherapy and treatment with two drugs, Perjeta and Herceptin, lengthens survival of patients with HER2-positive metastatic breast cancer by an average of nearly 16 months.
Lead researcher Dr. Sandra M. Swain said, "We've never seen results like this before in HER2-positive metastatic breast cancer. This unprecedented data gives patients with an aggressive disease hope to live a longer, better life."
During the study, patients received either Perjeta with Herceptin and chemotherapy or placebo with Herceptin and chemotherapy in the control group. The median overall survival for patients who received the Perjeta with Herceptin and chemotherapy was 56.5 months, compared with 40.8 months for those in the control group, a difference of 15.7 months. The study also revealed that the patients' cancer did not get worse for 6.3 months longer in the Perjeta group.
The study is published in the 'New England Journal of Medicine'.